Back

Epigenetic heritability of cell plasticity drives cancer drug resistance through one-to-many genotype to phenotype mapping

Fernandez-Mateos, J.; Milite, S.; Oliveira, E.; Vlachogiannis, G.; Chen, B.; Yara, E.; Cresswell, G. D.; James, C.; Patruno, L.; Ascolani, G.; Acar, A.; Heide, T.; Spiteri, I.; Graudenzi, A.; Caravagna, G.; Graham, T.; Magnani, L.; Valeri, N.; Sottoriva, A.

2023-11-16 cancer biology
10.1101/2023.11.15.567140 bioRxiv
Show abstract

Cancer drug resistance is multi-factorial, driven by heritable (epi)genetic changes but also phenotypic plasticity. Here we dissect it by perturbing colorectal cancer patient-derived organoids longitudinally with drugs in sequence. Combining longitudinal tracking, single cell omics, evolutionary modelling, and machine leaning, we found that different targeted drugs select for distinct subclones, supporting rationally designed drug sequences. The cellular memory was encoded as a heritable epigenetic configuration, from which multiple transcriptional programmes could run, supporting a one-to-many (epi)genotype-to- phenotype map that explains how clonal expansions and plasticity manifest together. This may ensure drug resistance subclones can exhibit distinct phenotypes in changing environments while still preserving the cellular memory encoding for their selective advantage. Chemotherapies resistance was instead entirely driven by plasticity. Inducing further chromosomal instability before drug application changed clonal evolution but not convergent transcriptional programmes. Collectively, our data show how genetic and epigenetic alterations are selected to "permissive epigenome" enabling phenotypic plasticity.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.